Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158132 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
NCT00158132: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00158132 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 199 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00158132, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
Study Summary
Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Amantadine, a medication that improves muscle control, and propranolol, a medication that lowers blood pressure, may be useful in treating cocaine addiction in individuals with severe cocaine withdrawal symptoms. This study will evaluate the effectiveness of amantadine and propranolol in preventing drug relapse among cocaine addicts.
Interventions
- DRUG Placebo
- DRUG Propranolol
- DRUG Amantadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 1999-09 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
What the finished NCT00158132 record still lists
NCT00158132 is an interventional study that assigns participants to a tested intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00158132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00158132 about?
NCT00158132 is a clinical study titled "Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2". Cocaine addiction is a serious health problem with no available medical treatment for preventing relapse. Amantadine, a medication that improves muscle control, and propranolol, a medication that lowers blood pressure, may be useful in treating cocaine addiction in individuals with severe cocaine wi...
What is the current status of trial NCT00158132?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 1999-09. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00158132?
The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG), Amantadine (DRUG).
Who is sponsoring clinical trial NCT00158132?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00158132's enrollment target sits among peer trials
199 349th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia